Abstract: Systems, devices, and techniques are described for analyzing evoked compound action potentials (ECAP) signals to assess the effect of a delivered electrical stimulation signal. In one example, a system includes a stimulation generator configured to deliver a stimulation pulse to a patient, sensing circuitry configured to sense an evoked compound action potential (ECAP) signal evoked from the stimulation pulse, and processing circuitry. The processing circuitry may be configured to determine a maximum value of a derivative of the ECAP signal, determine a minimum value of the derivative of the ECAP signal, determine, based on the maximum value of the derivative and the minimum value of the derivative, a characteristic value of the ECAP signal, and determine, based on the characteristic value of the ECAP signal, at least one parameter value at least partially defining electrical stimulation therapy to be delivered to the patient.

Abstract: Evoked compound action potentials (ECAPs) may be used to determine therapy. For example, a medical device includes stimulation generation circuitry and processing circuitry. The processing circuitry is configured to determine if a characteristic of a first ECAP is greater than a threshold ECAP characteristic value. Based on the characteristic of the first ECAP being greater than the threshold ECAP characteristic value, the processing circuitry is configured to decrease a parameter of a first set of pulses delivered by the stimulation generation circuitry after the first ECAP. Additionally, the processing circuitry is configured to determine if a characteristic of a second ECAP is less than the threshold ECAP characteristic value and based on the characteristic of the second ECAP being less than the threshold ECAP characteristic value, increase a parameter of a second set of pulses delivered by the stimulation generation circuitry after the second ECAP.

Abstract: Systems, devices, and techniques for adjusting electrical stimulation based on a posture state of a patient are described. For example, processing circuitry is configured to receive an input from a user adjusting an informed stimulation parameter that at least partially defines a plurality of informed pulses, determine a ratio of a first value of an informed stimulation parameter to a first value of a control stimulation parameter that at least partially defines a plurality of control pulses, change, according to the input, the first value of the informed stimulation parameter to a second value of the informed stimulation parameter, and change, based on the input and the ratio, the first value of the control stimulation parameter to a second value of the control stimulation parameter. The processing circuitry' can then control delivery of the adjusted control pulses and informed pulses.

Abstract: Compound of formula (1) and their pharmaceutically acceptable salts wherein A1,A2,R1, R2,R3,R4,X are as defined in the specification have excellent bradykinin antagonistic activity.

Abstract: A process for preparing halomethyl esters of penicillanic acid sulfone, intermediates to beta-lactamase inhibitors, from the corresponding substituted thiomethyl and sulfinylmethyl esters and a halogenating agent. The thiomethyl and sulfinylmethyl esters of penicillanic acid sulfone are useful intermediates.

Abstract: 6'-Aminopenicillanoyloxymethyl penicillanate 1,1-dioxide is prepared by a two-step procedure. The first step consists of coupling a salt of a 6-(protected amino)penicillanic acid with a halomethyl, an alkylsulfonyloxymethyl or an arylsulfonyloxymethyl ester of penicillanic acid 1,1-dioxide, to give a 6'-(protected amino)penicillanoyloxymethyl penicillanate 1,1-dioxide, wherein the protection at the 6-position has been achieved by coupling the 6-aminopenicillanic acid with a beta-dicarbonyl compound. The second step consists of removal of the protecting group on the 6'-amino group, using aqueous acid. 6'-Aminopenicillanoyloxymethyl penicillanate 1,1-dioxide is a chemical intermediate for preparing antibacterial agents. Also claimed are the 6'-(protected amino)penicillanoyloxymethyl penicillanate 1,1-dioxide compounds used as intermediates in the process of this invention.

Abstract: A process for preparing halomethyl esters of penicillanic acid sulfone, intermediates to beta-lactamase inhibitors, from the corresponding substituted thiomethyl and sulfinylmethyl esters and a halogenating agent. The thiomethyl and sulfinylmethyl esters of penicillanic acid sulfone are useful intermediates.